WHO Endorses GLP-1 Therapies for Obesity but Flags Access Barriers
The World Health Organization (WHO) has released its first-ever guideline recommending GLP-1 receptor agonists as part of long-term obesity treatment, reflecting a major shift in the global approach to managing one of the world’s fastest-growing health challenges. With more than one billion people now living with obesity, WHO’s guidance aims to expand scientifically validated treatment options while cautioning that access remains a critical obstacle.
Month: Current Affairs - December 04, 2025
Category: WHO guidelines, GLP-1 drugs